Cell fusion and hyperactive osteoclastogenesis in multiple myeloma

Advances in Experimental Medicine and Biology

Volumn 950, Issue , 2011, Pages 113-128

  Silvestris, Franco ^a   Ciavarella, Sabino ^a   Strippoli, Sabino ^a   Dammacco, Franco ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL SPECIFIC TRANSMEMBRANE PROTEIN; FLUOROURACIL; MELPHALAN; MEMBRANE PROTEIN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER STEM CELL; CELL DIFFERENTIATION; CELL FUSION; CENTROSOME; DENDRITIC CELL; HUMAN; MACROPHAGE; MONOCYTE; MULTIPLE MYELOMA; MYELOID PROGENITOR CELL; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHENOTYPE; PLASMA CELL; PLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; CYTOLOGY; PATHOLOGY; PHYSIOLOGY; REVIEW;

CELL DIFFERENTIATION; CELL FUSION; CENTROSOME; DENDRITIC CELLS; HUMANS; MULTIPLE MYELOMA; OSTEOCLASTS; PLASMA CELLS; PLOIDIES;

EID: 79960184516     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-0782-5_5     Document Type: Article

References (83)

1. Bjerkvig R, Tysnes BB, Aboody KS, et al. (2005) Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 5:899-904 (Pubitemid 41746034)
2. Lu X, Kang Y (2009) Cell fusion as a hidden force in tumor progression. Cancer Res 69:8536-8539
3. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497
4. Pawelek JM, Chakraborty AK (2008) The cancer cell-leukocyte fusion theory of metastasis. Adv Cancer Res 101:397-444
5. Oren-Suissa M, Podbilewicz B (2010) Evolution of programmed cell fusion: common mechanisms and distinct functions. Dev Dynam 239:1515-1528
6. Pawelek JM, Chakraborty AK (2008) Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer 8:377-386 (Pubitemid 351589699)
7. Duelli D, Lazebnik Y (2003) Cell fusion: a hidden enemy? Cancer Cell 3:445-448. (Pubitemid 38340291)
8. Miller FR, McInerney D, Rogers C, et al. (1988) Spontaneous fusion between metastatic mammary tumor subpopulations. J Cell Biochem 36:129-136 (Pubitemid 18034921)
9. Parris GE (2005) The role of viruses in cell fusion and its importance to evolution, invasion and metastasis of cancer clones. Med Hypotheses 64:1011-1014 (Pubitemid 40385961)
10. Duelli D, Lazebnik Y (2007) Cell-to-cell fusion as a link between viruses and cancer. Nat Rev Cancer 7:968-976 (Pubitemid 350165858)
11. Johansson CB, Youssef S, Koleckar K, et al. (2008) Extensive fusion of haematopoietic cells with Purkinje neurons in response to chronic inflammation. Nat Cell Biol 10:575-583 (Pubitemid 351627377)
12. Nygren JM, Liuba K, BreitbachM, et al. (2008) Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion. Nat Cell Biol 10:584-592 (Pubitemid 351627378)
13. Zelenin AV, Prudovski IA, Gumeniuk RR, et al. (1990) The nature of a proliferation block in differentiated cells with heterokaryons as a model: various types of absence of proliferation in cells in terminal differentiation. Ontogenez 21:32-40 (Pubitemid 20050243)
14. Yilmaz Y, Lazova R, Qumsiyeh M, et al. (2005) Donor Y chromosome in renal carcinoma cells of a female BMT recipient: visualization of putative BMT tumor hybrids by FISH. Bone Marrow Transplant 35:1021-1024 (Pubitemid 40711841)
15. Andersen TL, Boissy P, Sondergaard TE, et al. (2007) Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership? J Pathol 211:10-17 (Pubitemid 46092025)
16. Silvestris F, Ciavarella S, De Matteo M, et al. (2009) Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both? Oncologist 14:264-275
17. Zandecki M, Lai JL, Facon T, et al. (1996) Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 94:217-227
18. Fonseca R, Barlogie B, Bataille R, et al. (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64:1546-1558 (Pubitemid 38235629)
19. KuehlWM, Bergsagel PL (2002) Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2:175-187 (Pubitemid 37328787)
20. Chang WJ, Van Wier SA, Ahmann GJ, et al. (2005) A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 106:2156-2161 (Pubitemid 41291733)
21. Avet-Loiseau H, Facon T, Grosbois B, et al. (2002) Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99:2185-2191 (Pubitemid 34525505)
22. Fonseca R, Blood E, Rue M, et al. (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101:4569-4575 (Pubitemid 36857829)
23. Avet-Loiseau H, Brigaudeau C, Morineau N, et al. (1999) High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 24:9-15 (Pubitemid 28544457)
24. Smadja NV, Bastard C, Brigaudeau C, et al. (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98:2229-2238
25. Seong C, Delasalle K, Hayes K, et al. (1998) Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 101:189-194. (Pubitemid 28197793)
26. Castedo M, Perfettini JL, Roumier T, et al. (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene 23:2825-2837 (Pubitemid 38638845)
27. Vakifahmetoglu H, Olsson M, Tamm C, et al. (2008) DNA damage induces two distinct modes of cell death in ovarian carcinomas. Cell Death Differ 15:555-566 (Pubitemid 351267306)
28. Skwarska A, Augustin E, Konopa J (2007) Sequential induction of mitotic catastrophe followed by apoptosis in human leukemia MOLT4 cells by imidazoacridinone C-1311. Apoptosis 12:2245-2257 (Pubitemid 350077255)
29. Giehl M, Fabarius A, Frank O, et al. (2005) Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia 19:1192-1197 (Pubitemid 40946003)
30. Kramer A, Schweizer S, Neben K, et al. (2003) Centrosome aberrations as a possible mechanism for chromosomal instability in non-Hodgkins lymphoma. Leukemia 17:2207-2213 (Pubitemid 37428388)
31. LingleWL, Barrett SL, Negron VC, et al. (2002) Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 99:1978-1983 (Pubitemid 34169000)
32. Maxwell CA, Keats JJ, Belch AR, et al. (2005) Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Res 65:850-860 (Pubitemid 40216444)
33. Chang WJ, Ahmann GJ, Henderson K, et al. (2006) Clinical implication of centrosome amplification in plasma cell neoplasm. Blood 107:3669-3675
34. Chang WJ, Braggio E, Mulligan G, et al. (2007) The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that may benefit from aurora kinase inhibition. Blood 111:1603-1609 (Pubitemid 351213451)
35. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768
36. Agarwal JR, Matsui W (2010) Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. Anticancer Agents Med Chem 10:116-120
37. Dittmar T, Seidel J, Zaenker KS, et al. (2006) Carcinogenesis driven by bone marrow-derived stem cells. Contrib Microbiol 13:156-169
38. Miller FR, Mohamed AN, McEachern D (1989) Production of a more aggressive tumor cell variant by spontaneous fusion of two mouse tumor subpopulations. Cancer Res 49:4316-4321 (Pubitemid 19207279)
39. Duelli DM, Lazebnik YA (2000) Primary cells suppress oncogene-dependent apoptosis. Nat Cell Biol 2:859-862
40. Li R, Hehlmann R, Sachs R, et al. (2005) Chromosomal alterations cause the high rates and wide ranges of drug resistance in cancer cells. Cancer Genet Cytogenet 163:44-56 (Pubitemid 41597009)
41. Yagi M, Miyamoto T, Sawatani Y, et al. (2005) DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202:345-351 (Pubitemid 41126951)
42. Yilmaz Y, Lazova R, Qumsiyeh M, et al. (2005) Donor Y chromosome in renal carcinoma cells of a female BMT recipient. Bone Marrow Transplant 35:1021-1024.
43. Larizza L, Schirrmacher V, Graf L, et al. (1984) Suggestive evidence that the highly metastatic variant ESb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage. Int J Cancer 34:699-706
44. Pawelek JM (2007) Viewing malignant melanoma cells as macrophage-tumor hybrids. Cell Adh Migr 1:2-6
45. Pawelek J (2005) Tumor cell fusion as a source of myeloid traits in cancer. Lancet Oncol 6:988-993 (Pubitemid 41685232)
46. De Baetselier P, Roos E, Brys L, et al. (1984) Non-metastatic tumor cells acquire metastatic properties following somatic hybridization with normal cells. Cancer Metastasis Rev 3:5-24
47. Lu X, Kang Y (2007) Organotropism of breast cancer metastasis. J Mammary Gland Biol Neoplasia 12:153-162 (Pubitemid 47215433)
48. Horowitz MC, Lorenzo JA (2004) The origin of osteoclasts. Curr Opin Rheumatol 16:464-468
49. Miyamoto T (2006) The dendritic cell-specific transmembrane protein DC-STAMP is essential for osteoclast fusion and osteoclast bone-resorbing activity. Mod Rheumatol 16:341-342 (Pubitemid 44921579)
50. Yagi M, Miyamoto T, Sawatani Y, et al. (2005) DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202:345-351. (Pubitemid 41126951)
51. Yagi M, Miyamoto T, Toyama Y, et al. (2006) Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells. J Bone Miner Metab 24:355-358 (Pubitemid 44306170)
52. Matozaki T, Murata Y, Okazawa H, et al. (2009) Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol 19:72-80
53. Cui W, Cuartas E, Ke J, et al. (2007) CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts. Proc Natl Acad Sci USA 104:14436-14441 (Pubitemid 350003279)
54. Terpos E, PolitouM, Rahemtulla A (2003) New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 123:758-769 (Pubitemid 37533288)
55. Sezer O, Heider U, Zavrski I, et al. (2003) RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101:2094-2098 (Pubitemid 36302042)
56. Farrugia AN, Atkins GJ, To LB, et al. (2003). Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63:5438-5445 (Pubitemid 37139862)
57. Lai FP, Cole-Sinclair M, Cheng WJ, et al. (2004) Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 126:192-201 (Pubitemid 38961937)
58. Giuliani N, Colla S, Morandi F, et al. (2005) Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells. Haematologica 90:275-278 (Pubitemid 40293301)
59. Calvani N, Silvestris F, Cafforio P, et al. (2004) Osteoclast-like cell formation by circulating myeloma B lymphocytes: role of RANK-L. Leuk Lymphoma 45:377-380 (Pubitemid 38181444)
60. Seidel C, Hjertner O, Abildgaard N, et al. (2001) Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98:2269-2271
61. Lipton A, Ali SM, Leitzel K, et al. (2002) Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 8:2306-2310 (Pubitemid 34753605)
62. Terpos E, Politou M, Rahemtulla A (2005) The role of markers of bone remodelling in multiple myeloma. Blood Rev 19:125-142 (Pubitemid 40321139)
63. Silvestris F, Cafforio P, Calvani N, et al. (2006) In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma. Leuk Lymphoma 47:1921-1931 (Pubitemid 44649779)
64. Ghevaert C, Fournier M, Bernardi F, et al. (1997) Non-secretory multiple myeloma with multinucleated giant plasma cells. Leuk Lymphoma 27:185-189 (Pubitemid 27482936)
65. Zukerberg LR, Ferry JA, Conlon M, et al. (1990) Plasma cell myeloma with cleaved, multilobated and monocytoid nuclei. Am J Clin Pathol 93:657-661 (Pubitemid 20151124)
66. Kurabayashi H,Miyawaki S, Murakami H, et al. (1989) Ultrastructure of multinucleated giant myeloma cells: report of one case. Am J Hematol 31:284-285 (Pubitemid 19188528)
67. Buss DH, Reynolds GD, Cooper MR (1988) Multiple myeloma associated multilobated plasma cell nuclei. Virchows Arch B Cell Pathol Incl Mol Pathol 55:287-292
68. Durie BGM, Grogan TM, Spier C, et al. (1989) Myelomonocytic myeloma cell line (LB 84-1). Blood 73:770-776 (Pubitemid 19069183)
69. Duperray C, Klein B, Durie BGM, et al. (1989) Phenotypic analysis of human myeloma cell lines. Blood 73:566-572 (Pubitemid 19060544)
70. Liu S, Otsuyama K, Ma Z, et al. (2007) Induction of multilineage markers in human myeloma cells and their downregulation by IL-6. Int J Hematol 85:49-58 (Pubitemid 46193290)
71. Calvani N, Cafforio P, Silvestris F, et al. (2005) Functional osteoclast-like transformation of cultured human myeloma cell lines. Br J Haematol 130:926-938 (Pubitemid 43899733)
72. Silvestris F, Cafforio P, De Matteo M, et al. (2008) Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro. Leuk Res 32:611-623 (Pubitemid 351248954)
73. Silvestris F, Cafforio P, Tucci M, et al. (2002) Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 99: 1305-1313 (Pubitemid 34547085)
74. Tucci M, De Palma R, Lombardi L, et al. (2009) 3 integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells. Cancer Res 15;69:6738-6746
75. Ries WL, Gong JK, Gunsolley JC (1987) The distribution and kinetics of nuclei in rat osteoclasts. Cell Tissue Kinet 20:1-14 (Pubitemid 17060445)
76. Andersen TL, Søe K, Sondergaard TE, et al. (2010) Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. Br J Haematol 148:551-561
77. Alnaeeli M, Park J, Mahamed D, et al. (2007) Dendritic cells at the osteo-immune interface: implications for inflammation-induced bone loss. J Bone Miner Res 22:775-780 (Pubitemid 351339736)
78. Maitra R, Follenzi A, Yaghoobian A, et al. (2010) Dendritic cell-mediated in vivo bone resorption. J Immunol 185:1485-1491
79. Josselin N, Libouban H, Dib M, et al. (2009) Quantification of Dendritic Cells and Osteoclasts in the Bone Marrow of Patients with Monoclonal Gammopathy. Pathol Oncol Res 15:65-72
80. Wakkach A, Mansour A, Dacquin R, et al. (2008) Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts. Blood 112:5074-5083
81. Kukreja A, Hutchinson A, Dhodapkar K, et al. (2006) Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 203:1859-1865 (Pubitemid 44188460)
82. Kukreja A, Radfar S, Sun BH, et al. (2009) Dominant role of CD47-thrombospondin-1 interactions in myelomainduced fusion of human dendritic cells: implications for bone disease. Blood 114:3413-3421
83. Xie H, Ye M, Feng R, et al. (2004) Stepwise reprogramming of B cells into macrophages. Cell 117:663-676 (Pubitemid 38692531)